Cargando…

Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al.

Detalles Bibliográficos
Autor principal:	Mori, Nobuaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087153/ https://www.ncbi.nlm.nih.gov/pubmed/35562086 http://dx.doi.org/10.1016/j.cmi.2022.04.024

Ejemplares similares

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients
por: Chen, Ping-Jen, et al.
Publicado: (2021)

Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
por: Medisetty, Mahender Kumar, et al.
Publicado: (2021)

Re: Remdesivir for the treatment of COVID-19 by Lee et al.
por: Beccacece, Alessia, et al.
Publicado: (2023)

Re: ‘Post-COVID-19 chronic symptoms’ by Davido et al.
por: Miglis, Mitchell G., et al.
Publicado: (2021)

Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
por: Udwadia, Zarir F., et al.
Publicado: (2021)

Hematological Malignancy Patients, COVID-19, and Favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
por: Korman, Tony M.
Publicado: (2021)

Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al.
por: Koeckerling, David, et al.
Publicado: (2021)

Favipiravir Experience in Covid-19 Positive Myasthenia Gravis Patients
por: Yevgi, Recep, et al.
Publicado: (2021)

Re: Accelerating clinical trial implementation in the context of the COVID-19 pandemic by Diallo et al
por: Rys, Andrzej, et al.
Publicado: (2022)

Re: ‘Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients’ by Fiolet et al.
por: Lacout, Alexis, et al.
Publicado: (2021)

Re: ‘Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients’ by Fiolet et al.
por: Million, Matthieu, et al.
Publicado: (2021)

Re: ‘the unique COVID-19 presentation of patients with B cell depletion’ by Belkin et al.
por: Múñez-Rubio, Elena, et al.
Publicado: (2023)

Letter to the Editor re: Biglari et al. (2016)
por: Zura, Robert, et al.
Publicado: (2016)

ICU admission and favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Re: ‘efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis’ by Deng et al.
por: Zeng, Guangting, et al.
Publicado: (2023)

Re: ‘ESCMID COVID-19 living guidelines: drug treatment and clinical management’ by Bartoletti et al
por: Dauby, Nicolas
Publicado: (2022)

Re: ‘Methodological evaluation of bias in observational COVID-19 studies on drug effectiveness’ by Wolkewitz et al.
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2021)

Re: Latex Content in Adult Vaccines, J. Davenport et al., December 10, 2019
por: Hamilton, Gavin
Publicado: (2020)

Authors’ response: Re: Reifferscheid et al., “COVID-19 vaccine uptake and intention during pregnancy in Canada”
por: MacDonald, Shannon E., et al.
Publicado: (2022)

Re: 'Personal protective equipment protecting healthcare workers in the Chinese epicenter of COVID-19' by Zhao et al.
por: Wee, Liang En, et al.
Publicado: (2020)

Re: “High prevalence of heterotopic ossification in critically ill patients with severe COVID-19” by Stoira et al.
por: de l’Escalopier, Nicolas, et al.
Publicado: (2021)

An unusual case of bluish discoloration of the cornea after favipiravir therapy for COVID-19
por: Raiturcar, Tanvi P, et al.
Publicado: (2021)

Kaya et al. Is it a typical crosstalk: Need for re-implantation?
por: Akbarzadeh, Mohammad Ali
Publicado: (2015)

Re: ‘Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review’ by Serafim et al.
por: Lipes, Jed, et al.
Publicado: (2021)

Re: Hormonal therapies and venous thrombosis: The estrogen matters! Morimont et al.
por: LaVasseur, Corinne, et al.
Publicado: (2023)

Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia
por: Tatar, Erhan, et al.
Publicado: (2020)

Re: Post-COVID-19 syndrome and humoral response association after one year in vaccinated and unvaccinated patients by Peghin et al.
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Mortality in COVID-19 patients treated with ACEIs/ARBs: Re-estimated meta-analysis results following the Mehra et al. retraction
por: Alamer, Ahmad, et al.
Publicado: (2020)

Re: Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis' by Fiolet et al.
por: Vedrines, Nicolas, et al.
Publicado: (2021)

In Regard to Kil et al
por: Wada, Yuki, et al.
Publicado: (2023)

RE: “Efficacy of oral contrast agents for upper gastrointestinal signal suppression in MRCP: A systematic review of the literature” by Frisch et al.
por: Rajadurai, Suraindra, et al.
Publicado: (2018)

Re: ‘clinical characteristics of ambulatory and hospitalised patients with monkeypox virus infection’ by Mailhe et al.
por: Kherabi, Yousra, et al.
Publicado: (2023)

Re: Insomnia and Mild Cognitive Impairment
por: Mortazavi, S. M. J.
Publicado: (2018)

Use of Favipiravir in Lactating Mother With COVID-19
por: Karabayır, Nalan, et al.
Publicado: (2021)

Rebuttal to Peel et al. Re: ‘The imperative to develop a human vaccine for the Hendra virus in Australia’
por: Zahoor, Bilal
Publicado: (2016)

Letter to the editor re: Paratesticular sarcomas: a case series and literature review: Keenan et al
por: Floyd, Michael S., et al.
Publicado: (2019)

Rational Defensive Medicine: Putting an End to the Nationwide Favipiravir Debate
por: Öncel, Selim
Publicado: (2022)

Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019
por: Kumar, Pramod, et al.
Publicado: (2021)

Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial
por: Bosaeed, Mohammad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4ebdqrirattvk2vn3ph1s0401g